Through the agreement, EyePoint’s Yutiq and Dexycu products for eye surgery will be available to 9 million VA beneficiaries and federal employees. The contract will last five years.
“This new agreement with the VA further extends the commercial reach of Dexycu and Yutiq to patients suffering from ocular diseases in areas of high unmet medical need,” said Nancy Lurker, president and CEO of Watertown-Mass.-based EyePoint Pharmaceuticals.
More articles on supply chain:
ASC supply chain tip: Involve everybody in cost-cutting
IT provider for ASCs, hospitals installs nurse as director of operational excellence
Medline, HOTB Software Solutions partner to ease accreditation process
